OakChart

Annexon Inc

ANNXHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 11:23 AM ET

4.22+0.01 (0.17%)
2026-11-11 17:23 CET
Market cap
798.13 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-198.96 USD m
Free cash flow, TTM
-189.55 USD m
EPS diluted, TTM
-1.03
P/E
-
Compare

Price

ANNX against its 20, 50 and 200-day averages
2050200beatmiss
4.005.006.007.4M14.8MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ANNXclose 4.2220-day 3.9650-day 4.06200-day 5.134.22

41.3% under the 52-week high of 7.18 on 23 Jan 2026. 52-week low 2.54 on 13 Nov 2025. Last 15 sessions, 24.2% high to low

Profile

ANNX
52-week range, 36% of the way up
2.547.18

Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington's and alzheimer's disease, multiple sclerosis, glaucoma, parkinson's disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in Brisbane, CA.

IndexRUT
Employees96
IPOJul 24, 2020
Beta1.43
ATR, 14d0.26
Rel volume0.44
Short float17.57%
Insider own13.00%
Inst own90.19%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap799.49M
Enterprise Value659.31M
Income-198.96M
Sales0.00M
Book/sh0.75
Cash/sh1.13
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees96
IPOJul 24, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B5.61
P/C3.75
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio5.79
Current Ratio5.79
Debt/Eq0.51
LT Debt/Eq0.49
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.03
EPS next Y-1.00
EPS next Q-0.26
EPS this Y23.54%
EPS next Y2.84%
EPS next 5Y51.93%
EPS past 3/5Y19.69% 20.17%
Sales past 3/5Y- -
EPS Y/Y TTM26.90%
Sales Y/Y TTM-
EPS Q/Q32.04%
Sales Q/Q-
EarningsNov 09 AMC
EPS/Sales Surpr.10.65% -

Ownership

Insider Own13.00%
Insider Trans2.70%
Inst Own90.19%
Inst Trans12.98%
ROA-82.98%
ROE-130.80%
ROIC-93.52%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA206.56%
SMA503.76%
SMA200-17.72%
Trades-

Technical

Shs Outstand190.09M
Shs Float164.93M
Short Float17.57%
Short Ratio8.89
Short Interest28.98M
52W High7.18 -41.26%
52W Low2.54 66.03%
Volatility7.97% 7.20%
ATR (14)0.26
RSI (14)54.90
Beta1.43
Rel Volume0.44
Avg Volume3.26M
Volume469,999

Performance

Perf Week-2.61%
Perf Month10.11%
Perf Quarter-19.83%
Perf Half Y-22.62%
Perf YTD-15.99%
Perf Year41.99%
Perf 3Y98.46%
Perf 5Y-73.79%
Perf 10Y-
Recom1.36
Target Price17.00
Prev Close4.21
Price4.22
Change %0.17%

Analyst ratings

latest 10 of 17
DateActionAnalystRating changeTargetImplied
Aug 13, 2026UpgradeCCitizensMkt Underperform → Mkt Perform
Jul 21, 2026InitiatedCCitizensMkt Underperform$3-28.9%
May 12, 2026InitiatedGGoldmanNeutral$7+66.0%
Dec 23, 2025InitiatedCChardan Capital MarketsBuy$16+279.4%
Mar 01, 2024UpgradeJJP MorganNeutral → Overweight$11+160.8%
Dec 21, 2023UpgradeBBofA SecuritiesNeutral → Buy$4 → $6+42.3%
Oct 30, 2023InitiatedWWells FargoOverweight$11+160.8%
May 26, 2023DowngradeBBofA SecuritiesBuy → Neutral$8 → $3-28.9%
May 25, 2023DowngradeJJP MorganOverweight → Neutral$19 → $9+113.4%
Sep 16, 2022InitiatedJJefferiesBuy$12+184.5%

Peers

Mkt cap
TickerCompanyMkt cap
DNTHDianthus Therapeutics Inc5.04B
OMEROmeros Corp1.30B
IFRXInflaRx NV176.11M
ARGXArgen X SE ADR61.16B
IMVTImmunovant Inc7.65B
EYPTEyePoint Inc32.09M
PRTAProthena Corp Plc443.14M
KODKodiak Sciences Inc6.94B
AKTXAkari Therapeutics Plc ADR13.52M
RLYBRallybio Corp85.08M

Insider trading

latest 14 of 37
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Love DouglasPRESIDENT AND CEOSep 24 '26Buy3.8326,06599,829390,476Sep 25 04:15 PM
WIGGANS THOMAS GFormer DirectorAug 13 '26Proposed Sale5.302,00010,596Aug 13 03:34 PM
WIGGANS THOMAS GFormer DirectorJul 15 '26Proposed Sale6.322,00012,630Jul 15 04:19 PM
WIGGANS THOMAS GFormer DirectorJul 14 '26Proposed Sale5.611,0005,605Jul 14 01:56 PM
Yednock TedEVP & CHIEF INNOVATION OFFICERJun 11 '26Option Exercise1.8530,64656,698184,807Jun 15 04:15 PM
Satter Muneer ADirectorMay 28 '26Buy5.41613,4973,319,01910,342,134May 29 05:21 PM
Carson William H.DirectorMay 11 '26Buy5.788,00046,24078,405May 13 04:30 PM
Carson William H.DirectorApr 10 '26Buy6.208,00049,60070,405Apr 14 04:16 PM
Carson William H.DirectorMar 10 '26Buy5.678,00045,36062,405Mar 12 04:31 PM
Dananberg JamieCHIEF MEDICAL OFFICERMar 02 '26Sale5.435,82031,603123,582Mar 04 04:30 PM
Overdorf MichaelEVP & CHIEF BUSINESS OFFICERMar 02 '26Sale5.424,33923,517182,625Mar 04 04:30 PM
Yednock TedEVP & CHIEF INNOVATION OFFICERMar 02 '26Sale5.425,56630,168154,161Mar 04 04:30 PM
ARTIS DEAN RICHARDEVP & CHIEF SCIENTIFIC OFFICERMar 02 '26Sale5.435,89432,004180,093Mar 04 04:30 PM
Lew JenniferEVP & CHIEF FINANCIAL OFFICERMar 02 '26Sale5.425,56530,162170,700Mar 04 04:30 PM

Held by

AUM
TickerCompanyAUM
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
IBBiShares Biotechnology ETFAUM: 11.36B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
DFASU.S. Small Cap Portfolio-ETF Class Shares-

News

latest 14 of 206
  • Annexon Reports Third Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones (GlobeNewswire)
  • Annexon to Host Virtual Investor Event on November 3, 2026: Vonaprument for the Treatment of Geographic Atrophy - Highlighting Key Aspects of Phase 3 ARCHER II Trial (GlobeNewswire) +7.45%
  • Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.28% +17.60%
  • Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting (GlobeNewswire)
  • Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.11%
  • Loading…
  • Annexon to Participate in Upcoming September Investor Conferences (GlobeNewswire)
  • Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Annexon shares fall as second-quarter loss exceeds Wall Street forecasts (InvestorsHub)
  • Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones (GlobeNewswire)
  • Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study (GlobeNewswire)
  • Annexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its Board of Directors (GlobeNewswire)
  • Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week (GlobeNewswire)
  • Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance (GlobeNewswire) +8.44%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-09-0.250-0.280-0.2500.000.0011
2026Q22026-08-12-0.280-0.239-0.2750.000.0010
2026Q12026-05-07-0.230-0.283-0.2270.000.0010
2025Q42026-03-30-0.280-0.313-0.2760.000.0010
2025Q32025-11-10-0.370-0.341-0.3680.000.008
2025Q22025-08-14-0.340-0.366-0.3440.000.008
2025Q12025-05-12-0.370-0.297-0.3670.000.008
2024Q42025-03-03-0.330-0.270-0.3290.000.008
2024Q32024-11-14-0.250-0.258-0.2490.000.008
2024Q22024-08-12-0.230-0.230-0.2280.000.008
2024Q12024-05-13-0.210-0.340-0.2050.000.008
2023Q42024-03-26-0.360-0.436-0.3570.000.008
2023Q32023-11-13-0.430-0.502-0.4310.000.008
2023Q22023-08-07-0.470-0.544-0.4680.000.008
2023Q12023-05-08-0.520-0.517-0.5240.000.008
2022Q42023-03-06-0.480-0.527-0.4750.000.008

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-4.150-3.060-4.1470.000.00
2021FY-3.400-3.353-3.4010.000.00
2022FY-2.600-2.676-2.5960.000.00
2023FY-1.770-1.851-1.7740.000.00
2024FY-1.010-0.955-1.0060.000.00
2025FY-1.340-1.378-1.3420.000.00
2026FY--1.025--0.00
2027FY--0.996--26.82
2028FY--0.149--257.5
2029FY-1.187--660.58
2030FY-2.518--1,100

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-106000.000.000.00
2026Q4S2026-11-096000.000.000.00
2026Q4S2026-08-316000.000.000.00
2026Q4S2026-08-125000.000.000.00
2026Q4S2026-07-304000.000.000.00
2026Q4S2026-07-205000.000.000.00
2026Q4S2026-07-094000.000.000.00
2026Q4S2026-05-315000.000.000.00
2026Q4S2026-05-115010.000.000.00
2026Q4S2026-05-084010.000.000.00
2026Q4S2026-03-313010.000.000.00
2026Q4S2026-03-172017.500.0015.00
2026Q4S2026-01-252009.704.4015.00
2026Q4S2026-01-132019.704.4015.00

Estimate history

EPS, annual-0.492-0.484-1.002-4.147-3.401-2.596-1.774-1.006-1.345-1.0292
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.249-0.329-0.367-0.344-0.368-0.276-0.227-0.275-0.25
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0000000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual38.22138.22138.22138.15838.56147.72378.369109.382149.363190.093
Period201720182019202020212022202320242025MRQ
Shares, quarterly105.71109.382109.714109.832115.123149.363162.502174.604190.093
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A3.853.693.453.273.313.410.670.490.49
Gross Profit-3.85-3.69-3.45-3.27-3.31-3.41-0.67-0.49-0.49
Selling, General and Administrative Excl. Other201.92212.72150.62140.46142.29127.3062.8032.0218.66
Research and Development166.40184.70119.45113.76112.50100.0749.2724.5215.53
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-205.78-216.41-154.07-143.72-145.60-130.71-63.47-32.52-19.15
Interest Expense0.830.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.005.67-0.26
Net Income Before Taxes-198.96-206.69-138.20-134.24-141.95-130.32-63.41-37.18-18.30
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-198.96-206.69-138.20-134.24-141.95-130.32-63.41-37.18-18.30
Net Income From Continuing Operations-198.96-206.69-138.20-134.24-141.95-130.32-63.41-37.18-18.30
Net Income-198.96-208.55-138.20-134.24-141.95-130.32-70.34-38.28-18.48
EPS (Recurring)-0.97-1.34-1.01-1.77-2.60-3.40-4.15-0.90-0.49
EPS (Basic, Before Extraordinaries)-1.03-1.34-1.01-1.77-2.60-3.40-4.15-1.00-0.48
EPS (Diluted)-1.03-1.34-1.01-1.77-2.60-3.40-4.15-1.00-0.48
EBITDA-201.92-212.72-150.62-140.46-142.29-127.30-62.80-32.02-18.66
Non-Operating Income (Expense)7.649.7215.879.493.650.390.061.010.58
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense17.3816.4219.4318.1818.5216.264.891.490.30
Shares Outstanding190.09149.36109.3878.3747.7238.5638.1638.2238.22
Market Capitalization798.13798.13546.83355.65246.25440.93955.081,054.68-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.980.970.960.940.930.910.900.88
Gross Profit-0.98-0.97-0.96-0.94-0.93-0.91-0.90-0.88
Selling, General and Administrative Excl. Other51.2656.2545.1049.3156.0950.8156.5151.60
Research and Development41.3746.5935.7942.6649.7044.1648.1843.35
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-52.24-57.23-46.05-50.26-57.02-51.73-57.41-52.48
Interest Expense0.830.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-51.22-55.35-44.14-48.26-54.92-49.16-54.36-48.59
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-51.22-55.35-44.14-48.26-54.92-49.16-54.36-48.59
Net Income From Continuing Operations-51.22-55.35-44.14-48.26-54.92-49.16-54.36-48.59
Net Income-51.22-55.35-44.14-48.26-54.92-51.01-54.36-48.59
EPS (Recurring)-0.25-0.28-0.23-0.28-0.37-0.34-0.37-0.33
EPS (Basic, Before Extraordinaries)-0.25-0.28-0.23-0.28-0.37-0.34-0.37-0.33
EPS (Diluted)-0.25-0.28-0.23-0.28-0.37-0.34-0.37-0.33
EBITDA-51.26-56.25-45.10-49.31-56.09-50.81-56.51-51.60
Non-Operating Income (Expense)1.851.881.912.002.102.573.053.89
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense5.114.814.163.313.834.215.085.22
Shares Outstanding190.09174.60162.50149.36115.12109.83109.71109.38
Market Capitalization798.13935.54801.80726.54335.16263.31211.74546.83

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments238.34312.02259.72242.66242.72351.2143.9344.172.97
Short Term Receivables0.000.000.000.000.000.000.080.230.58
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets3.854.444.145.444.982.801.401.311.34
Total Current Assets242.19316.46263.86248.10247.69354.0145.4145.714.89
Net Property, Plant & Equipment25.8029.3432.7835.9738.181.942.142.352.82
Total Investments and Advances1.031.031.031.031.170.000.000.000.00
Intangible Assets--0.000.000.000.00---
Other Assets8.553.230.000.000.000.002.350.100.11
Total Assets277.57350.07297.67285.10287.04355.9549.9048.157.82
Short Term Debt Incl. Current Port. of LT Debt2.912.522.171.321.200.000.000.000.00
Accounts Payable14.9310.435.497.4211.153.732.371.271.52
Other Current Liabilities24.7917.5710.2813.639.396.892.562.061.39
Total Current Liabilities42.6330.5117.9322.3621.7410.624.933.332.92
Long Term Debt23.2926.4529.1931.5433.390.000.00107.2248.97
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.001.051.441.802.15
Total Liabilities65.9256.9747.1253.9055.1311.676.37112.3554.03
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00143.980.000.00
Common Equity211.65293.11250.56231.19231.91344.28-100.45-64.20-46.21
Total Shareholders Equity211.65293.11250.56231.19231.91344.2843.53-64.20-46.21
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity211.65293.11250.56231.19231.91344.2843.53-64.20-46.21
Total Liabilities & Stockholders Equity277.57350.07297.67285.10287.04355.9549.9048.157.82
Book Value Per Share1.422.683.204.846.019.02-2.63-1.68-1.21
Tangible Book Value Per Share1.422.683.204.846.019.02-2.63-1.68-1.21
Full-Time Employees961007180614824--
Price to Book Ratio5.601.641.540.941.912.772.89--
Return on Assets-65.86-42.67-46.07-49.62-40.54-31.25-75.85-65.41-
Return on Equity-81.90-50.84-55.73-61.30-45.24-32.70---
Return on Invested Capital-87.98-43.25-47.99-54.03-49.12-18.42-85.42-42.55-677.83
Quick Ratio5.6810.3714.7211.1011.3933.339.2113.741.68
Current Ratio5.6810.3714.7211.1011.3933.339.2113.741.68

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-198.96-206.69-138.20-134.24-141.95-130.32-63.41-37.18-18.30
Depreciation3.853.693.453.273.313.410.670.490.49
Other Funds (Non Cash)15.6112.4210.3815.6318.5917.524.947.710.15
Funds from Operations-179.50-190.59-124.37-115.34-120.05-109.39-57.80-28.98-17.67
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-9.914.236.36-5.803.743.284.720.620.48
Cash from Operating Activities-189.41-186.36-118.01-121.14-116.31-106.11-53.09-28.36-17.19
Capital Expenditures-0.14-0.14-0.01-0.19-6.53-1.65-0.46-0.27-0.02
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments-59.86190.19-218.7870.9064.97-86.58-82.700.000.00
Purchase of Investments-191.36-212.21-583.93-108.09-113.20-225.60-82.700.000.00
Sale Or Maturity of Investments131.50402.40365.15178.98178.17139.020.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-60.00190.05-218.8070.7058.44-88.24-83.16-0.27-0.02
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock162.99108.86161.21135.52122.911.79360.8830.0058.46
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock162.99108.86161.21135.52122.911.79360.8830.0058.46
Proceedsfrom Stock Options161.40108.39159.97135.43122.830.18360.850.000.12
Issuance or Reduction of Debt, Net49.390.000.000.000.000.000.000.000.00
Change in Long Term Debt49.390.000.000.000.000.000.000.000.00
Issuance of Long Term Debt49.390.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.00-1.600.00
Other Financing Activities Uses0.000.000.000.000.000.000.00-1.600.00
Cash from Financing Activities212.37108.86161.21135.52122.911.79360.8828.3958.46
Exchange Rate Effect0.000.00-0.010.010.00-0.010.01-0.01-0.04
Net Change in Cash-37.03112.55-175.6185.0965.04-192.56224.63-0.2441.21
Free Cash Flow-189.55-186.49-118.02-121.33-122.83-107.76-53.55-28.62-17.21
Preferred Dividends (Cash Flow)--0.000.000.000.00---
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments213.37209.24225.03238.34188.72227.02
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets4.533.513.243.854.103.60
Total Current Assets217.90212.76228.27242.19192.82230.62
Net Property, Plant & Equipment23.0524.0124.8725.8026.7427.62
Total Investments and Advances1.031.031.031.031.031.03
Other Assets8.438.278.728.558.555.30
Total Assets250.41246.07262.89277.57229.14264.57
Short Term Debt Incl. Current Port. of LT Debt3.243.133.022.912.822.72
Accounts Payable15.9115.7317.5314.9318.2211.52
Other Current Liabilities18.5119.6215.3924.7922.5426.41
Total Current Liabilities37.6638.4835.9442.6343.5840.64
Long Term Debt69.9521.5222.4223.2924.1224.91
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities107.6160.0158.3565.9267.7065.56
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity142.79186.06204.53211.65161.44199.02
Total Shareholders Equity142.79186.06204.53211.65161.44199.02
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity142.79186.06204.53211.65161.44199.02
Total Liabilities & Stockholders Equity250.41246.07262.89277.57229.14264.57
Book Value Per Share0.751.071.261.421.401.81
Tangible Book Value Per Share0.751.071.261.421.401.81
Full-Time Employees-92-9699103
Price to Book Ratio5.604.543.913.581.681.08
Return on Assets-82.98-79.38-69.44-65.86-68.11-55.74
Return on Equity-130.80-105.26-87.65-81.90-83.99-66.75
Return on Invested Capital-24.07-26.66-19.45-20.54-29.60-21.95
Quick Ratio5.795.536.355.684.425.67
Current Ratio5.795.536.355.684.425.67

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-51.22-55.35-44.14-48.26-54.92-49.16
Depreciation0.980.970.960.940.930.91
Other Funds (Non Cash)4.654.553.522.883.362.95
Funds from Operations-45.59-49.82-39.66-44.43-50.63-45.30
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-3.091.81-7.13-1.50-1.687.22
Cash from Operating Activities-48.68-48.01-46.80-45.93-52.30-38.07
Capital Expenditures0.00-0.140.000.00-0.05-0.01
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-100.5040.1027.06-26.5245.9273.10
Purchase of Investments-110.50-9.90-5.94-65.02-26.68-58.70
Sale Or Maturity of Investments10.0050.0033.0038.5072.60131.80
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-100.5039.9727.06-26.5245.8773.08
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.00---
Change in Capital Stock2.9132.1032.9095.0813.560.15
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock2.9132.1032.9095.0813.560.15
Proceedsfrom Stock Options2.5131.5432.6794.6813.560.15
Issuance or Reduction of Debt, Net49.390.000.000.000.000.00
Change in Long Term Debt49.390.000.000.000.000.00
Issuance of Long Term Debt49.390.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities52.3032.1032.9095.0813.560.15
Exchange Rate Effect0.000.000.000.000.000.00
Net Change in Cash-96.8824.0613.1622.637.1335.17
Free Cash Flow-48.68-48.14-46.80-45.93-52.35-38.09

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3017.57%29.0M164.9M3.13M
2026-10-1519.18%31.6M164.9M2.95M
2026-09-3019.41%32.0M164.9M3.28M
2026-09-1519.93%32.9M165.0M3.57M
2026-08-3119.45%32.1M165.0M3.57M
2026-08-1420.23%32.6M161.1M3.59M
2026-07-3121.59%30.8M142.5M3.49M
2026-07-1520.93%29.8M142.5M3.35M
2026-06-3020.78%29.6M142.5M2.94M
2026-06-1518.52%26.4M142.5M2.58M
2026-05-2918.13%25.8M142.5M2.55M
2026-05-1517.00%24.3M142.9M2.53M
2026-04-3016.33%23.4M143.6M2.58M
2026-04-1513.88%19.7M141.8M2.60M
2026-03-3113.12%18.6M142.1M2.69M
2026-03-1312.80%16.4M128.2M2.59M
2026-02-2712.41%15.9M128.2M2.59M
2026-02-1312.59%16.1M128.2M2.91M
2026-01-3013.43%17.2M128.2M2.88M
2026-01-1514.39%18.4M128.2M2.82M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call1.000.805.500.000.0000.000.000.958-0.0300.001
call2.000.003.601.9515.55410.000.000.898-0.0380.001
call3.000.103.701.2517.2315.000.000.839-0.0260.002
call4.000.251.000.503.4705,1230.000.644-0.0470.002
call5.000.150.200.151.75233730.000.309-0.0230.002
call6.000.000.500.202.5042270.000.244-0.0290.002
call7.000.002.550.103.0882.000.000.213-0.0330.002
put1.000.002.550.008.9820.000.00-0.042-0.0300.001
put2.000.000.300.137.2104.000.00-0.111-0.0480.001
put3.000.000.200.052.8311050.00-0.162-0.0250.002
put4.000.000.750.503.3493550.00-0.358-0.0460.002
put5.000.403.400.0011.9260.000.00-0.688-0.0220.002
put6.000.004.300.0012.0770.000.00-0.757-0.0280.002
put7.000.505.200.0012.2110.000.00-0.647-0.0590.002

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0910-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-098-KCurrent report2026-11-09SEC
2026-11-05SCHEDULE 13G/ASEC
2026-09-254Statement of changes in beneficial ownership of securities2026-09-24SEC
2026-08-13144Filing for proposed sale of securities under Rule 144.SEC
2026-08-124Statement of changes in beneficial ownership of securities2026-08-10SEC
2026-08-123Initial statement of beneficial ownership of securities2026-08-10SEC
2026-08-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-128-KCurrent report2026-08-12SEC
2026-08-108-KCurrent report2026-08-10SEC
2026-08-07SCHEDULE 13GSEC
2026-08-068-KCurrent report2026-08-06SEC
2026-07-308-KCurrent report2026-07-30SEC
2026-07-27SCHEDULE 13G/ASEC
2026-07-15144Filing for proposed sale of securities under Rule 144.SEC
2026-07-14144Filing for proposed sale of securities under Rule 144.SEC
2026-07-08SCHEDULE 13G/ASEC
2026-07-08SCHEDULE 13G/ASEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-128-KCurrent report2026-06-11SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-28SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-134Statement of changes in beneficial ownership of securities2026-05-11SEC
2026-05-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-0999.83K100
2026-080000
2026-070000
2026-060000
2026-053.37M200
2026-0449.60K100
2026-0345.36K1147.45K5
2026-0200165.97K5
2026-010000
2025-12177.32K300
2025-118.66M500

Institutional holders

Manager% owned
FMR LLC14.19%
BlackRock, Inc.8.26%
Redmile Group, LLC7.24%
STATE STREET CORP6.00%
BVF INC/IL5.31%
Woodline Partners LP4.23%
VANGUARD CAPITAL MANAGEMENT LLC4.19%
MAK CAPITAL ONE LLC3.58%
GOLDMAN SACHS GROUP INC3.56%
Siren, L.L.C.2.72%

Funds

Fund% owned
State Street(R) SPDR(R) S&P(R) Biotech ETF3.80%
Select Biotechnology Portfolio3.26%
VANGUARD TOTAL STOCK MARKET INDEX FUND3.03%
iShares Russell 2000 ETF2.48%
Fidelity Stock Selector Small Cap Fund1.26%
Fidelity Small Cap Growth Fund1.09%
VANGUARD EXTENDED MARKET INDEX FUND1.07%
Fidelity Small Cap Index Fund1.04%
Fidelity Advisor Biotechnology Fund1.01%
iShares Russell 2000 Growth ETF0.87%

OakChart. ANNX. Cached 15 minutes.